Different programmed cell death-ligand 1 (PD-L1) assays and scoring algorithms are being used in the evaluation of PD-L1 expression for the selection of patients for immunotherapy in specific settings of advanced urothelial carcinoma (UC). In this paper, we sought to investigate three approved assays (Ventana SP142 and SP263, and Dako 22C3) in UC with emphasis on implications for patient selection for atezolizumab/pembrolizumab as the first line of treatment. Tumors from 124 patients with invasive UC of the bladder were analyzed using tissue microarrays (TMA). Serial sections were stained with SP263 and SP142 on Ventana Benchmark Ultra and with 22C3 on Dako Autostainer Link 48. Stains were evaluated independently by two observers and scored using the combined positive score (CPS) and tumor infiltrating immune cells (IC) algorithms. Differences in proportions (DP), overall percent agreement (OPA), positive percent agreement (PPA), negative percent agreement (NPA), and Cohen kappa were calculated for all comparable cases. Good overall concordance in analytic performance was observed for 22C3 and SP263 with both scoring algorithms; specifically, the highest OPA was observed between 22C3 and SP263 (89.6%) when using CPS. On the other hand, SP142 consistently showed lower positivity rates with high differences in proportions (DP) compared with 22C3 and SP263 with both CPS and IC, and with a low PPA, especially when using the CPS algorithm. In conclusion, 22C3 and SP263 assays show comparable analytical performance while SP142 shows divergent staining results, with important implications for the selection of patients for both pembrolizumab and atezolizumab.

Comparison of three validated PD-L1 immunohistochemical assays in urothelial carcinoma of the bladder: interchangeability and issues related to patient selection / Munari, Enrico; Querzoli, Giulia; Brunelli, Matteo; Marconi, Marcella; Sommaggio, Marco; Cocchi, Marco A; Martignoni, Guido; Netto, George J; Calio, Anna; Quatrini, Linda; Mariotti, Francesca R; Luchini, Claudio; Girolami, Ilaria; Eccher, Albino; Segala, Diego; Ciompi, Francesco; Zamboni, Giuseppe; Moretta, Lorenzo; Bogina, Giuseppe. - In: FRONTIERS IN IMMUNOLOGY. - ISSN 1664-3224. - 13:(2022), pp. 1-9. [10.3389/fimmu.2022.954910]

Comparison of three validated PD-L1 immunohistochemical assays in urothelial carcinoma of the bladder: interchangeability and issues related to patient selection

Eccher, Albino;
2022

Abstract

Different programmed cell death-ligand 1 (PD-L1) assays and scoring algorithms are being used in the evaluation of PD-L1 expression for the selection of patients for immunotherapy in specific settings of advanced urothelial carcinoma (UC). In this paper, we sought to investigate three approved assays (Ventana SP142 and SP263, and Dako 22C3) in UC with emphasis on implications for patient selection for atezolizumab/pembrolizumab as the first line of treatment. Tumors from 124 patients with invasive UC of the bladder were analyzed using tissue microarrays (TMA). Serial sections were stained with SP263 and SP142 on Ventana Benchmark Ultra and with 22C3 on Dako Autostainer Link 48. Stains were evaluated independently by two observers and scored using the combined positive score (CPS) and tumor infiltrating immune cells (IC) algorithms. Differences in proportions (DP), overall percent agreement (OPA), positive percent agreement (PPA), negative percent agreement (NPA), and Cohen kappa were calculated for all comparable cases. Good overall concordance in analytic performance was observed for 22C3 and SP263 with both scoring algorithms; specifically, the highest OPA was observed between 22C3 and SP263 (89.6%) when using CPS. On the other hand, SP142 consistently showed lower positivity rates with high differences in proportions (DP) compared with 22C3 and SP263 with both CPS and IC, and with a low PPA, especially when using the CPS algorithm. In conclusion, 22C3 and SP263 assays show comparable analytical performance while SP142 shows divergent staining results, with important implications for the selection of patients for both pembrolizumab and atezolizumab.
2022
13
1
9
Comparison of three validated PD-L1 immunohistochemical assays in urothelial carcinoma of the bladder: interchangeability and issues related to patient selection / Munari, Enrico; Querzoli, Giulia; Brunelli, Matteo; Marconi, Marcella; Sommaggio, Marco; Cocchi, Marco A; Martignoni, Guido; Netto, George J; Calio, Anna; Quatrini, Linda; Mariotti, Francesca R; Luchini, Claudio; Girolami, Ilaria; Eccher, Albino; Segala, Diego; Ciompi, Francesco; Zamboni, Giuseppe; Moretta, Lorenzo; Bogina, Giuseppe. - In: FRONTIERS IN IMMUNOLOGY. - ISSN 1664-3224. - 13:(2022), pp. 1-9. [10.3389/fimmu.2022.954910]
Munari, Enrico; Querzoli, Giulia; Brunelli, Matteo; Marconi, Marcella; Sommaggio, Marco; Cocchi, Marco A; Martignoni, Guido; Netto, George J; Calio, Anna; Quatrini, Linda; Mariotti, Francesca R; Luchini, Claudio; Girolami, Ilaria; Eccher, Albino; Segala, Diego; Ciompi, Francesco; Zamboni, Giuseppe; Moretta, Lorenzo; Bogina, Giuseppe
File in questo prodotto:
File Dimensione Formato  
fimmu-13-954910.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 3.8 MB
Formato Adobe PDF
3.8 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1317488
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact